Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Francesca Patriarca

6PUBLICATIONS
28CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Respiratory diseasesCancer therapy (excl. chemotherapy and radiation therapy)Pharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

Sort by Publication Date:
|Jul 02, 2026
Early software-assisted response predicts survival in a prospective cohort of 258 newly diagnosed cGvHD patients.

|Mar 10, 2026
Bispecific antibodies followed by allogeneic hematopoietic stem cell transplantation as rescue therapy in refractory/relapsed B cell non-Hodgkin lymphoma: a real-life experience.

Gabriele Facchin, Marta Lisa Battista, Jacopo Olivieri

|Jan 27, 2026
Adherence to oral immunosuppressors using therapeutic drug monitoring: A retrospective study.

Xhesika Ikonomi, Chiara Visintini, Margherita Venturini

|Jul 27, 2025
Real-world study in steroid-refractory acute graft versus host disease: Comparison of efficacy and tolerability of ruxolitinib alone or ruxolitinib in association with extracorporeal photopheresis or extracorporeal photopheresis monotherapy.

Marta Lisa Battista, Gabriele Facchin, Maria De Martino

|Jan 04, 2020
Bortezomib, cyclophosphamide, dexamethasone versus lenalidomide, cyclophosphamide, dexamethasone in multiple myeloma patients at first relapse.

Vittorio Montefusco, Alessandro Corso, Monica Galli

|Nov 28, 2018
Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib.

Michael Mian, Norbert Pescosta, Stefania Badiali

Pageof 1

Frequent Collaborators

3 joint publications

Miriam Isola

2 joint publications

Marta Lisa Battista

2 joint publications

Gabriele Facchin

2 joint publications

Michele Malagola

2 joint publications

Francesco Saraceni

2 joint publications

Franca Fagioli

2 joint publications

Maria Teresa Lupo-Stanghellini

1 joint publications

Francesca Bonifazi

1 joint publications

Patrizia Mondello

1 joint publications

Vittorio Montefusco

Frequent Collaborators

3 joint publications

Miriam Isola

2 joint publications

Marta Lisa Battista

2 joint publications

Gabriele Facchin

2 joint publications

Michele Malagola